IL-1 blockade has been used in the treatment of MIS-C and KD, and recently anti-IL-1Ra autoantibodies have been described in over 60% of MIS-C patients while absent in healthy controls and patients with COVID-19 (33). The gene discussed is IL1B; the disease is COVID-19.